caa a22 4500 469073918 CHVBK 20180323132929.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741145 doi (NATIONALLICENCE)springer-10.1007/BF01741145 Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancer [Elektronische Daten] First evaluation of clinical response of a phase II-trial [Peter Schlag, Maria Manasterski, Thomas Gerneth, Peter Hohenberger, Margret Dueck, Christian Herfarth, Winfrid Liebrich, Volker Schirrmacher] Summary: A group of 23 colorectal cancer patients were treated by a new type of active specific immunotherapy (ASI) following complete surgical resection of liver metastases (R0 resection). For ASI treatment we used a vaccine consisting of 1 × 107 autologous, irradiated (200 Gy) metastases-derived tumor cells incubated with 32 hemagglutination units (HU) of Newcastle disease virus (NDV). The adjuvant vaccine therapy was started 2 weeks after surgery and was repeated five times at 14-days intervals followed by one boost 3 months later. The delayed-type hypersensitivity (DTH) skin reactions to the vaccine were measured as well as the DTH reactions to a challenge test of 1 × 107 non-virus-modified autologous tumor cells from liver metastases or 1 × 107 autologous normal liver cells. In addition 32 HU NDV alone and a standard antigen test (Merieux test) were applied pre- and post-vaccination. The vaccination was well tolerated. In 13 of 23 patients an increasing reactivity against the vaccine was observed during the vaccination procedure. Nine patients (40%) experienced an increased DTH reactivity against autologous tumor cells following vaccination, while 17% or fewer showed an increased reactivity to Merieux test antigens, NDV, or normal liver cells. The increased antitumor response was not correlated to responsiveness to NDV alone, autologous liver cells, enzymes and culture medium used for vaccine preparation or standard antigens (Merieux test). After a follow-up of at least 18 months 61% of the vaccinated patients developed tumor recurrence in comparison to 87% of a matched control groups from the same institution that had been only surgically treated. The results of this phase II trial are encouraging and should stimulate further prospective randomized studies. Springer-Verlag, 1992 Active specific immunotherapy nationallicence Colorectal cancer nationallicence Liver metastases nationallicence Schlag Peter Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut Manasterski Maria Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut Gerneth Thomas Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut Hohenberger Peter Department of Surgery, University of Heidelberg, Heidelberg, Germany aut Dueck Margret Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut Herfarth Christian Department of Surgery, University of Heidelberg, Heidelberg, Germany aut Liebrich Winfrid Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut Schirrmacher Volker German Cancer Research Center, Division of Genetics and Immunology, Heidelberg, Germany aut Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 325-330 0340-7004 35:5<325 1992 35 262 https://doi.org/10.1007/BF01741145 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741145 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schlag Peter Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Manasterski Maria Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Gerneth Thomas Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Hohenberger Peter Department of Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Dueck Margret Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Herfarth Christian Department of Surgery, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Liebrich Winfrid Section of Surgical Oncology, University of Heidelberg, Heidelberg, Germany aut NATIONALLICENCE 700 1- Schirrmacher Volker German Cancer Research Center, Division of Genetics and Immunology, Heidelberg, Germany aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/5(1992-09-01), 325-330 0340-7004 35:5<325 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer